Drugs / GenSci094
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06095206 | Sep → Nov 2023 | infertility disorder | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06561594 | Sep → Nov 2024 overdue | hypogonadotropic hypogonadism | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06091436 | Mar → Dec 2023 | infertility disorder | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci094 | “GenSci094 was administered for 12 weeks” NCT06561594 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection（GenSci094）” NCT06095206 ↗ |
| Route | Subcutaneous | “a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.” NCT06091436 ↗ |